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aneurysms was first raised about 20 years ago.1
Since, then Vascular Surgeons have endeavoured to
show that population screening is worthwhile. Three
large randomised control trials have now all shown
that screening men aged 65–74 years reduces the
mortality from abdominal aortic aneurysm by at least
40%.2–4 Screening does not appear to be detrimental to
quality of life.2 There is also ample evidence from
community-wide programmes, such as the Glouces-
tershire project, that such screening is feasible and
effective.5 The remaining issue to be considered is cost.
In this issue of the Journal, Jes Lindholt and
colleagues report on the cost-effectiveness analysis of
the Danish trial of screening for aortic aneurysms.6
The trial involved 12,639 men aged 64–73 years,
randomly allocated to an invitation for screening or
to be a control. At a mean follow-up of 52 months, the
risk of death from abdominal aortic aneurysm was
reduced by an impressive 67%.4 A simple but
pragmatic economic analysis, based on the costs of
screening, surveillance and surgery for aortic aneur-
ysms yielded an estimate of £6090 per life-year saved
at 5 years.
This magnitude of cost compares favourably with
screening mammography for breast cancer.7 It is
similar to that estimated using Markov modelling of
screening for aneurysms8 but is considerably less than
the £28,000 per life-year gained over 4 years (or about
£36,000 per quality adjusted life-year) reported in
the multicentre aneurysm screening study (MASS).9
The reasons for the differences between the two
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trial. The costs associated with surgery in the Danish
trial were based on a relatively imprecise Diagnostic
Related Group (major vessel surgery outside the
heart). The authors argue that this is representative
of actual costs on the basis of an earlier validation
exercise. However, their estimates are probably not
conservative and did not include additional costs such
as related re-admissions within 12 months of the
original surgery. In addition, exercises such as quality
adjustment weighting, discounting and sensitivity
analysis (an assessment of the uncertainty of esti-
mates) are not reported. Irrespective of the initial
costings, the long-term cost-effectiveness of screening
for aortic aneurysms is likely to improve dramatically
with time due to cumulative survival benefit. In the
Danish study the cost per life-year saved fell to £1227
at 15 years and in a recent analysis of the MASS data, a
figure as low as £676 per quality-adjusted life-year
gained has been reported at 30 years.10
In the Danish trial, the prevalence of ‘abdominal
aortic aneurysm-associated diseases’ was lower in
men failing to attend following an invitation to
screening. This is surprising and is in contrast to
both MASS and the Western Australian trial where the
non-attenders were at much greater risk of death from
aortic aneurysm than those attending and this
consequently reduced some of the benefit of screening.
A phenomenon that was observed in all three trials,
and is currently being re-assessed, is an apparent
reduction in all-cause mortality in the screened
groups. The cause of this and its impact on cost-
benefit is not known.
The cost-effectiveness of screening will vary in
differing health systems. For example, in Australia,
there has been long-standing universal availability of
open-access imaging (ultrasound and CT scanning).Eur J Vasc Endovasc Surg 32, 7–8 (2006)
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P. E. Norman and J. Golledge8This has resulted in a relatively high level of incidental
detection and treatment of AAAs over the last two
decades which in turn reduced the effectiveness of
screening.3 Another important variable in the cost
equation is the extent to which endovascular rather
than open aneurysm repair is used.11
Until the aetiology of abdominal aortic aneurysm is
better understood and either primary or secondary
prevention becomes possible, screening men aged 65
years may the best way to save lives. As the cost
appears to be reasonable it is now time for govern-
ments and their policy-makers to make decisions.Acknowledgements
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